Blincyto (blinatumomab)

pCPA File Number: 21121

Negotiation Status:

Concluded with an LOI

Indication(s):

Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)

Sponsor/Manufacturer:

Amgen Canada Inc.

CDA-AMC Project Number:

PC0146-000

pCPA Engagement Letter Issued:

2019-07-04

Negotiation Process Concluded:

2019-09-25